Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-04-16

Clinical Trial Update: Pharmacokinetics and Bioequivalence Study of Empagliflozin+Metformin Hydrochloride 5 mg/850 mg Film-coated Tablets (Gedeon Richter Plc., Hungary) Versus Synjardy® 5 mg/850 mg Film-coated Tablets (Boehringer Ingelheim International GmbH, Germany) [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetics and bioequivalence study comparing Gedeon Richter's Empagliflozin+Metformin HCl 5 mg/850 mg tablets with Synjardy 5 mg/850 mg tablets; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Empagliflozin + Metformin HCl 5 mg/850 mg Film-coated Tablets (empagliflozin/metformin hydrochloride)
  • Synjardy 5 mg/850 mg film-coated tablets (empagliflozin/metformin hydrochloride)

Snippet

Sponsor: Gedeon Richter Plc. | Conditions: Diabetes Mellitus Type 2 | Phase 1 | Status: COMPLETED